Form 8-K - Current report:
SEC Accession No. 0000950170-24-124563
Filing Date
2024-11-12
Accepted
2024-11-12 07:17:09
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nmra-20241112.htm   iXBRL 8-K 41074
2 EX-99.1 nmra-ex99_1.htm EX-99.1 131315
3 GRAPHIC img49001591_0.jpg GRAPHIC 1874
  Complete submission text file 0000950170-24-124563.txt   303227

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20241112.xsd EX-101.SCH 25999
15 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20241112_htm.xml XML 4941
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 241443257
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)